1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow SparingVision: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy SPVN20 (high dose), SPVN20 (medium dose), SPVN20 (low dose) - Retinitis Pigmentosa (RP), Rod Cone Dystrophy | Phase 1 / Phase 2 | Recruiting | SparingVision | 27 | 2025-10-08 | 2026-09-08 |
| Promising ROd-cone DYstrophy Gene therapY SPVN06 - Retinitis Pigmentosa | Phase 1 / Phase 2 | Active not recruiting | SparingVision | 33 | 2023-04-12 | 2026-05-15 |
Cone-Rod Dystrophies (2) · Eye Diseases (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Retinal Dystrophies (2) · Retinitis Pigmentosa (2)
France (2) · Belgium (1) · Ireland (1) · United States (1)
2025 (1)